Skip to main content
Journal cover image

Impact of lapatinib plus trastuzumab versus single-agent lapatinib on quality of life of patients with trastuzumab-refractory HER2+ metastatic breast cancer.

Publication ,  Journal Article
Wu, Y; Amonkar, MM; Sherrill, BH; O'Shaughnessy, J; Ellis, C; Baselga, J; Blackwell, KL; Burstein, HJ
Published in: Ann Oncol
December 2011

BACKGROUND: Progression-free survival (PFS) was significantly longer for the lapatinib plus trastuzumab (L+T) arm than for L alone in a phase III, randomized, open-label study of women with human epidermal growth factor receptor 2 positive metastatic breast cancer who had documented progression on at least one T-containing regimen in the metastatic setting. This analysis focused on impact of treatments on health-related quality of life (HRQOL). METHODS: HRQOL was assessed using the Functional Assessment of Cancer Therapy-Breast (FACT-B) questionnaire. Changes from baseline and time to deterioration were analyzed in the intent-to-treat population. RESULTS: Differences between the treatment arms in adjusted mean change from baseline favored the L+T arm, ranging from 0.0 to 4.1 (FACT-B), 1.0-4.0 [Functional Assessment of Cancer Therapy-General (FACT-G)], and 0.5-2.7 (Trial Outcome Index). Most differences were not statistically significant, except for FACT-G at week 12 (delta = 4.0, P = 0.037). Similar results were found in a sensitivity analysis that included HRQOL records up to patient withdrawal from original randomized treatment. The longer time to HRQOL deterioration in the L+T arm was not statistically significant (FACT-B hazard ratio, 0.82; 95% confidence interval 0.56-1.20). CONCLUSION: The addition of lapatinib to trastuzumab prolonged PFS while improving or maintaining near-term HRQOL, suggesting a meaningful clinical benefit to patients.

Duke Scholars

Published In

Ann Oncol

DOI

EISSN

1569-8041

Publication Date

December 2011

Volume

22

Issue

12

Start / End Page

2582 / 2590

Location

England

Related Subject Headings

  • Treatment Outcome
  • Trastuzumab
  • Surveys and Questionnaires
  • Receptor, erbB-2
  • Receptor, ErbB-2
  • Quinazolines
  • Quality of Life
  • Oncology & Carcinogenesis
  • Neoplasm Metastasis
  • Lapatinib
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Wu, Y., Amonkar, M. M., Sherrill, B. H., O’Shaughnessy, J., Ellis, C., Baselga, J., … Burstein, H. J. (2011). Impact of lapatinib plus trastuzumab versus single-agent lapatinib on quality of life of patients with trastuzumab-refractory HER2+ metastatic breast cancer. Ann Oncol, 22(12), 2582–2590. https://doi.org/10.1093/annonc/mdr014
Wu, Y., M. M. Amonkar, B. H. Sherrill, J. O’Shaughnessy, C. Ellis, J. Baselga, K. L. Blackwell, and H. J. Burstein. “Impact of lapatinib plus trastuzumab versus single-agent lapatinib on quality of life of patients with trastuzumab-refractory HER2+ metastatic breast cancer.Ann Oncol 22, no. 12 (December 2011): 2582–90. https://doi.org/10.1093/annonc/mdr014.
Wu Y, Amonkar MM, Sherrill BH, O’Shaughnessy J, Ellis C, Baselga J, et al. Impact of lapatinib plus trastuzumab versus single-agent lapatinib on quality of life of patients with trastuzumab-refractory HER2+ metastatic breast cancer. Ann Oncol. 2011 Dec;22(12):2582–90.
Wu, Y., et al. “Impact of lapatinib plus trastuzumab versus single-agent lapatinib on quality of life of patients with trastuzumab-refractory HER2+ metastatic breast cancer.Ann Oncol, vol. 22, no. 12, Dec. 2011, pp. 2582–90. Pubmed, doi:10.1093/annonc/mdr014.
Wu Y, Amonkar MM, Sherrill BH, O’Shaughnessy J, Ellis C, Baselga J, Blackwell KL, Burstein HJ. Impact of lapatinib plus trastuzumab versus single-agent lapatinib on quality of life of patients with trastuzumab-refractory HER2+ metastatic breast cancer. Ann Oncol. 2011 Dec;22(12):2582–2590.
Journal cover image

Published In

Ann Oncol

DOI

EISSN

1569-8041

Publication Date

December 2011

Volume

22

Issue

12

Start / End Page

2582 / 2590

Location

England

Related Subject Headings

  • Treatment Outcome
  • Trastuzumab
  • Surveys and Questionnaires
  • Receptor, erbB-2
  • Receptor, ErbB-2
  • Quinazolines
  • Quality of Life
  • Oncology & Carcinogenesis
  • Neoplasm Metastasis
  • Lapatinib